Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial by Roberts Jason D, Wells George A, Le May Michel R, Labinaz Marino, Glover Chris, Froeschl Michael, Dick Alexander, Marquis Jean-Francois, O'Brien Edward, Goncalves Sandro, Druce Irena, Stewart Alexandre, Gollob Michael H, So Derek Y F in Lancet (2012).

[PMID: 22464343] PubMed


Prospective assessment of pharmacogenetic strategies has been limited by an inability to undertake bedside genetic testing. The CYP2C19*2 allele is a common genetic variant associated with increased rates of major adverse events in individuals given clopidogrel after percutaneous coronary intervention (PCI). We used a novel point-of-care genetic test to identify carriers of the CYP2C19*2 allele and aimed to assess a pharmacogenetic approach to dual antiplatelet treatment after PCI.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Dosing Information

No dosing information annotated.